



P.O. Box 25010  
Little Rock, AR 72221

[Revision log](#)  
[Coding Implications](#)

# CONCERT GENETIC ONCOLOGY: CANCER SCREENING

---

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

## OVERVIEW

This policy relates to genetic and biomarker tests that aim to screen for specific cancers in individuals who are at risk to develop them. These screening tests can be designed for asymptomatic individuals that are at an average risk level for cancer, or for individuals that are known to be at a higher risk to develop a specific cancer. Genetic and biomarker cancer screening tests aim to identify the presence of cancer before symptoms appear and when treatment is often most effective. These tests are not currently diagnostic for cancer but typically determine if an individual has an increased chance that cancer is present.

Screening tests for colorectal cancer may be performed by analyzing specific DNA present in fecal matter or peripheral blood. Cancer screening tests may also be performed on urine samples to screen for bladder cancer and colon polyps. These methods offer a noninvasive alternative to currently available screening approaches such as colonoscopy.

Screening tests for lung cancer are potentially useful adjuncts to the [low-dose computed tomography \(LDCT\)](#), a recommended lung cancer screening tool in high-risk populations. Biomarkers such as autoantibodies, metabolites, proteins, and [microRNA](#) may be sampled from many different bodily sources, including whole blood, serum, plasma, bronchial brushings, and sputum. Circulating blood-based and serum-based biomarkers are convenient samples as they are relatively easy and inexpensive to collect.

It is important to note that screening tests are not diagnostic tests. The results from a screening test put an individual into a lower risk or higher risk status. For an individual that is put into the higher risk status, following up with an appropriate diagnostic test would be necessary to make a definitive diagnosis of cancer.

For lung cancer, approaches where a biomarker based initial screen is followed by [LDCT](#), or in which a biomarker test is combined with LDCT, show promise for use in early detection.



P.O. Box 25010  
Little Rock, AR 72221

However, more high-quality evidence is needed to support and guide the implementation of these tests.

## POLICY REFERENCE TABLE

### Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2023, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

The tests, associated laboratories, CPT codes, and ICD codes contained within this document serve only as examples to help users navigate claims and corresponding criteria; as such, they are not comprehensive and are not a guarantee of coverage or non-coverage. Please see the Concert Platform for a comprehensive list of registered tests.

<a href="#">Criteria Sections</a>	Example Tests (Labs)	Common CPT Codes	Common ICD Codes	<a href="#">Ref</a>
<b><a href="#">Colorectal Cancer Screening Tests</a></b>				
<a href="#">FIT-DNA Testing (Stool DNA Testing)</a>	Cologuard (Exact Sciences Corporation, LLC)	81528	Z12.10-Z12.13	1, 2
<a href="#">Urinary Biomarker Tests for Pre-cancerous Colon Polyps</a>	PolypDx (Metabolomic Technologies)	0002U	Z12.10-Z12.13	1
<a href="#">Blood-based Biomarker Colorectal Cancer Screening Tests</a>	BeScreened-CRC (Beacon Biomedical)	0163U	Z12.10-Z12.13	4
	FirstSight (CellMax Life)	0091U		
	ColonSentry (StageZero Life Sciences)	81599		
	Epi proColon (Epigenomics)	81327, G0327		
	ColoVantage (Quest Diagnostics)			
	ColoScape Colorectal Cancer Detection (DiaCarta Clinical Lab)	0368U		



P.O. Box 25010  
Little Rock, AR 72221

	Guardant Shield (Guardant Health)	81479		
<a href="#">Lung Cancer Screening Tests</a>				
<a href="#">Blood-based Biomarker Lung Cancer Screening Tests</a>	FirstLook (Delfi Diagnostics)		Z12.2	3

## OTHER RELATED POLICIES

This policy document provides criteria for cancer screening tests. Please refer to:

- **Oncology: Molecular Analysis of Solid Tumors and Hematologic Malignancies** for criteria related to DNA testing of a solid tumor or a blood cancer.
- **Genetic Testing: Hereditary Cancer Susceptibility Syndromes** for criteria related to genetic testing to determine if an individual has an inherited cancer susceptibility syndrome.
- **Oncology: Algorithmic Testing** for criteria related to gene expression profiling and tumor multianalyte assays with algorithmic analyses.
- **Oncology: Circulating Tumor DNA and Circulating Tumor Cells (Liquid Biopsy)** for criteria related to circulating tumor DNA (ctDNA) or circulating tumor cell testing performed on peripheral blood for cancer diagnosis, management and surveillance.
- **Genetic Testing: General Approach to Genetic and Molecular Testing** for criteria related to cancer screening that is not specifically discussed in this or another non-general policy.

[back to top](#)

## CRITERIA

It is the policy of health plans affiliated with Centene Corporation® that the specific genetic testing noted below is **medically necessary** when meeting the related criteria:

### COLORECTAL CANCER SCREENING TESTS

#### FIT-DNA Testing (Stool DNA Testing)

- I. The use of [FIT-DNA Testing](#) (stool DNA testing) (81528) to screen for colorectal cancer may be considered **medically necessary** when:
  - A. The member/enrollee is 45 years of age or older, **AND**
  - B. The member/enrollee is an individual who is at average risk for colorectal cancer, because the member/enrollee does not have any of the following:



P.O. Box 25010  
Little Rock, AR 72221

1. A personal history of colorectal cancer or adenoma or sessile serrated polyp, **OR**
2. A family history of colorectal cancer in close relatives, **OR**
3. A personal history of inflammatory bowel disease (ulcerative colitis or Crohn's disease), **OR**
4. A personal history of cystic fibrosis, **OR**
5. A confirmed or suspected hereditary colorectal cancer syndrome, such as familial adenomatous polyposis (FAP) or Lynch syndrome (hereditary non-polyposis colon cancer or HNPCC), **OR**
6. A personal history of receiving radiation to the abdomen (belly) or pelvic area to treat a prior cancer.

- II. The use of [FIT-DNA](#) Testing (stool DNA testing) (81528) to screen for colorectal cancer is considered **investigational** for all other indications.

**NOTE:** Fecal immunochemical testing (FIT) alone is not in the scope of this policy (see [definitions](#))

[back to top](#)

#### Urinary Biomarker Tests for Pre-cancerous Polyps

- I. The use of urinary biomarker tests for pre-cancerous polyps (0002U) is considered **investigational**.

[back to top](#)

#### Blood-based Biomarker Colorectal Cancer Screening Tests

- I. The use of blood-based biomarkers to screen for colorectal cancer (0091U, 0163U, 0368U, 81599, G0327) is considered **investigational**.
- II. The use of 81479 (Guardant Shield) and 81327 (Epi Pro Colon) testing **may be considered medically necessary** when:
  1. The member's age is 45-85 years, and,
  2. The member is asymptomatic (no signs or symptoms of colorectal disease including but not limited to lower gastrointestinal pain, blood in stool, positive guaiac fecal occult blood test or fecal immunochemical test), and,



P.O. Box 25010  
Little Rock, AR 72221

3. The member is at average risk of developing colorectal cancer (no personal history of adenomatous polyps, colorectal cancer, or inflammatory bowel disease, including Crohn's Disease and ulcerative colitis; no family history of colorectal cancers or adenomatous polyps, familial adenomatous polyposis, or hereditary nonpolyposis colorectal cancer).

[back to top](#)

## LUNG CANCER SCREENING TESTS

### Blood-based Biomarker Lung Cancer Screening Tests

- I. The use of blood-based biomarker tests for lung cancer screening are considered **investigational**.

[back to top](#)

## DEFINITIONS

1. **Fecal immunohistochemical testing (FIT):** Screening test for colon cancer that detects human blood in the lower intestines. (FIT testing alone does not involve any genetic test and is outside of the scope of this policy).
2. **FIT-DNA test:** Combination of the fecal immunochemical (FIT), which uses antibodies to detect blood in the stool, with a test that detects abnormal DNA from cancer or polyp cells in the stool.
3. **Low-dose computed tomography (LDCT):** Proposed as a method of screening asymptomatic, high-risk individuals for lung cancer; it refers to a non-contrast study with a multi-detector CT scanner during a single maximal inspiratory breath-hold with a scanning time of under 25 seconds. It has been suggested that LDCT may be an improved early lung cancer detection tool based on the advantages it appears to have over CXR and sputum cytology to detect lung cancer at an earlier stage.
4. **MicroRNAs (miRNAs):** Tissue specific, small, non-coding RNAs regulating gene expression which may identify candidates for early detection of lung cancer.

[back to top](#)

## BACKGROUND AND RATIONALE

### COLON CANCER SCREENING TESTS

#### FIT-DNA Testing (Stool DNA Testing)



P.O. Box 25010  
Little Rock, AR 72221

### *National Comprehensive Cancer Network (NCCN)*

Current NCCN guidelines on Colorectal Cancer Screening (1.2024) support the use of FIT-DNA for colorectal cancer screening in average-risk individuals aged 45-75 with a life expectancy greater than or equal to 10 years, and notes that the decision to screen individuals aged 76-85 should be individualized. (p. CSCR-1A). The choice of screening modality should be based on patient preference and availability after discussion. (p. CSCR-1).

### *Food and Drug Administration (FDA)*

*Cologuard (Exact Sciences):*

On August 12, 2014, Cologuard (Exact Sciences) was approved by the U.S. Food and Drug Administration (FDA) through the premarket approval process as an automated fecal DNA testing product (P130017). Cologuard is intended for the qualitative detection of colorectal neoplasia associated with DNA markers and occult hemoglobin in human stool. A positive result may indicate the presence of CRC or advanced adenoma and should be followed by diagnostic colonoscopy. (p. 1)

On September 20, 2019, the FDA approved the expansion of the Cologuard label to include adults ages 45 years or older. Cologuard was previously indicated for those aged 50 years or older. Cologuard is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.

### **Urinary Biomarker Tests for Pre-cancerous Colon Polyps**

*National Comprehensive Cancer Network (NCCN)*

Current NCCN guidelines on Colon Cancer Screening (1.2024) do not include a recommendation for colorectal cancer screening via urine-based screening.

There is insufficient evidence to support the use of this test. No recommendations for or against this testing within standard professional society guidelines covering this area of testing were identified.

### **Blood-based Biomarker Colorectal Cancer Screening Tests**

*Concert Evidence Review for Coverage Determination (Published 12/21/2023)*

Multiple studies have been published on BeScreened, FirstSight CRC, ColonSentry, Epi proColon, Colovantage, ColoScape Colorectal Cancer Detection, and Guardant Shield and their ability to screen for increased risk of colorectal cancer, including several meta-analyses and validation studies. Most of these studies include a measure of clinical validity measured by sensitivity and



P.O. Box 25010  
Little Rock, AR 72221

specificity, and several studies compared these measures to those of colonoscopy, FIT or FOBT testing. The evidence for clinical validity does not consistently demonstrate superior sensitivity or specificity for these tests across studies. This lack of consistency highlights the importance of understanding the mechanism of these biomarkers in colorectal cancer in order to explain the observed variability. Further, there is limited evidence to demonstrate that these tests promote a safe and effective alternative to colonoscopy or useful screening test to prioritize patients who should get colonoscopies. While the United States Preventive Services Task Force (USPSTF) and the National Comprehensive Cancer Network (NCCN) address blood-based tests for colon cancer screening in their most recent recommendations, neither recommend the testing.

At the present time, the following blood-based biomarker tests are not FDA approved: BeScreened, FirstSight CRC, ColonSentry, Colovantage, ColoScape and Colorectal Cancer and have INSUFFICIENT EVIDENCE in peer-reviewed publications to effectively result in improved health outcomes compared to the current standard of care.

Consistent with Arkansas legislation, Epi Pro Colon and Guardant Shield are covered as FDA approved testing. The plan highly recommends providers follow CMS national coverage determination guidelines for testing, which only covers Guardant Shield.

## LUNG CANCER SCREENING TESTS

### Blood-based Biomarker Lung Cancer Screening Tests

*National Comprehensive Cancer Network (NCCN)*

Current NCCN guidelines on Lung Cancer Screening (2.2024) do not include a recommendation for lung cancer screening via blood-based or micro-RNA based screening. Current NCCN guidelines support lung cancer screening using LDCT for individuals with high risk factors.

There is insufficient evidence to support the use of this test. No recommendations for or against this testing within standard professional society guidelines covering this area of testing were identified.

[back to top](#)

Reviews, Revisions, and Approvals	Revision Date	Approval Date
Policy developed.	03/23	03/23
Semi-annual review. Updated title to reflect V1.2024 version. Overview, coding, reference-table, background and references updated. Throughout policy: replaced "coverage criteria" with "criteria. For Policy Reference Table; Cancer Screening Tests: added G0328. For Other Related Policies: added "and Molecular". For Criteria; Blood-based Biomarker Colorectal Cancer Screening Tests: added G0327 and G0328. For	10/23	10/23



P.O. Box 25010  
Little Rock, AR 72221

Background and Rationale; Colon Cancer Screening Tests- Blood-based Biomarker Colorectal Cancer Screening Tests: removed “Technical Assessment 2021”; removed “October 2021...”; added “May 2023.”		
Semi-annual review. Updated title to reflect V2.2024 version. Minor rewording for clarity throughout. Coding, reference-table, background and references updated.	04/24	04/24
Semi-annual review. Updated title to reflect V1.2025 version. Urinary Biomarker Tests for Pre-cancerous Colon Polyps: Reformatted Background and Rationale; Updated NCCN version. Blood-based Biomarker Colorectal Cancer Screening Tests: Streamlined portions of Background and Rationale section for brevity; Updated NCCN version. Blood-based Biomarker Lung Cancer Screening Tests: Updated example test in Policy Reference Table; Streamlined and clarified portions of Background and Rationale section. FIT-DNA Testing (Stool DNA Testing): Updated NCCN version in Background and Rationale and references.	11/24	11/24
Updated for AR specific: Clarified Guardant Shield and Epi Pro Colon coverage and updated background information on epi-pro colon not covered for CMS NCD	1/25	1/25

## REFERENCES

1. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Colorectal Cancer Screening. Version 1.2024.  
[https://www.nccn.org/professionals/physician\\_gls/pdf/colorectal\\_screening.pdf](https://www.nccn.org/professionals/physician_gls/pdf/colorectal_screening.pdf)
2. Summary of Safety and Effectiveness Data (SSED): Cologuard. U.S. Food & Drug Administration website. Available at:  
[https://www.accessdata.fda.gov/cdrh\\_docs/pdf13/P130017B.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130017B.pdf).
3. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology for Lung Cancer Screening. Version 2.2024.  
[https://www.nccn.org/professionals/physician\\_gls/pdf/lung\\_screening.pdf](https://www.nccn.org/professionals/physician_gls/pdf/lung_screening.pdf)
4. Concert. Evidence Review for Coverage Determination for ColoRectal Cancer Blood Based Biomarker Tests. Published 12/21/2023.

### **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon





P.O. Box 25010  
Little Rock, AR 72221

in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. "Health Plan" means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care and are solely responsible for the medical advice and treatment of member/enrollees. This clinical policy is not intended to recommend treatment for member/enrollees. Member/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, member/enrollees, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, member/enrollees and their representatives agree to be bound by such terms and conditions by providing services to member/enrollees and/or submitting claims for payment for such services.



P.O. Box 25010  
Little Rock, AR 72221

**Note: For Medicaid member/enrollees**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

**Note: For Medicare member/enrollees**, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs and LCDs and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.

[back to top](#)